A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients

NCT00402233 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

312

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson Disease

Interventions

DRUG: Pramipexole
DRUG: Placebo

Sponsor

Boehringer Ingelheim